Scribd
Upload
6 views1 page

Tenecteplase vs Alteplase in Thrombosis

This meta-analysis evaluates the clinical efficacy of tenecteplase (TNK) compared to alteplase (rt-PA) for treating cerebral arterial thrombosis. Results indicate that TNK, particularly at a dosage of 0.25 mg/kg, significantly improves major neurological function and reduces parenchymal hematoma compared to rt-PA. The study concludes that TNK is a more effective treatment option than rt-PA for this condition.

Uploaded by

kasha.gouthami
Copyright
© All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PDF, TXT or read online on Scribd
6 views1 page

Tenecteplase vs Alteplase in Thrombosis

This meta-analysis evaluates the clinical efficacy of tenecteplase (TNK) compared to alteplase (rt-PA) for treating cerebral arterial thrombosis. Results indicate that TNK, particularly at a dosage of 0.25 mg/kg, significantly improves major neurological function and reduces parenchymal hematoma compared to rt-PA. The study concludes that TNK is a more effective treatment option than rt-PA for this condition.

Uploaded by

kasha.gouthami
Copyright
© All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PDF, TXT or read online on Scribd

8/9/2020 Therapeutic effect of tenecteplase on treatment of cerebral arterial thrombosis: a meta-analysis - PubMed

FULL TEXT LINKS

Meta-Analysis Eur Rev Med Pharmacol Sci. 2016 Oct;20(20):4369-4379.

Therapeutic effect of tenecteplase on treatment of


cerebral arterial thrombosis: a meta-analysis
Y Zang 1 , J Hou, L-Y Wang

Affiliations
PMID: 27831633
Free article

Abstract
Objective: To evaluate the clinical efficacy between tenecteplase (TNK) and alteplase (rt-PA).
Furthermore, suitable dosage of TNK in cerebral arterial thrombosis treatment was explored.

Materials and methods: The studies met with the predefined selection criteria were selected for the
present study. The quality of each study was evaluated by Cochrane quality evaluation. The outcome
indexes including early major neurological improvement (MNI), excellent recovery, good recovery,
recanalization at 24 hours-complete or partial, symptomatic intracranial hemorrhage, any
parenchymal hematoma and deaths were analyzed by using RevMan and Stata statistical software,
under a random-effects model or a fixed-effects model. The safety and efficacy between TNK and rt-
PA were investigated. Furthermore, the clinical efficacy outcomes between different dosages of TNK
were evaluated. Sensitivity analysis was performed to evaluate the reliability.

Results: A total of 6 studies were enrolled for the present study. Compared with the 0.1 mg/kg TNK
group, 0.25 mg/kg TNK group had a significantly better MNI (RR = 0.66, 95% CI: [0.49, 0.88], p =
0.005) and excellent recovery (RR = 0.71, 95% CI: [0.53, 0.95], p = 0.02). TNK group achieved an
increased MNI (RR = 1.59, 95% CI: [1.08, 2.34], p = 0.02) and a reduced parenchymal hematoma (RR =
0.26, 95% CI: [0.10, 0.71], p = 0.009) than rt-PA group.

Conclusions: Compared with rt-PA, TNK could better improve the major neurological function. TNK
0.25 mg/kg had a better clinical treatment effect than TNK 0.1 mg/kg.

Related information
MedGen
PubChem Compound (MeSH Keyword)

LinkOut - more resources


Full Text Sources
European Review for Medical and Pharmacological Sciences

Medical
Genetic Alliance
MedlinePlus Health Information
Research Materials
NCI CPTC Antibody Characterization Program
Miscellaneous
NCI CPTAC Assay Portal

[Link] 1/1

You might also like